Clever chemistry

Why seed investor Merck Ventures returned for Inthera's series A round

Three of Inthera Bioscience AG's seed investors returned for a CHF10.5 million ($10.8 million) series A round to bring the company's lead protein-protein interaction inhibitor to the clinic.

Merck Ventures led the round, which closed on

Read the full 365 word article

How to gain access

Continue reading with a
two-week free trial.